WO2005051307A3 - Epha2 agonistic monoclonal antibodies and methods of use thereof - Google Patents

Epha2 agonistic monoclonal antibodies and methods of use thereof Download PDF

Info

Publication number
WO2005051307A3
WO2005051307A3 PCT/US2004/039112 US2004039112W WO2005051307A3 WO 2005051307 A3 WO2005051307 A3 WO 2005051307A3 US 2004039112 W US2004039112 W US 2004039112W WO 2005051307 A3 WO2005051307 A3 WO 2005051307A3
Authority
WO
WIPO (PCT)
Prior art keywords
epha2
methods
cancer
antibodies
monoclonal antibodies
Prior art date
Application number
PCT/US2004/039112
Other languages
French (fr)
Other versions
WO2005051307A2 (en
Inventor
Michael S Kinch
Kelly Carles-Kinch
Jane C Stewart
Original Assignee
Medimmune Inc
Purdue Research Foundation
Michael S Kinch
Kelly Carles-Kinch
Jane C Stewart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc, Purdue Research Foundation, Michael S Kinch, Kelly Carles-Kinch, Jane C Stewart filed Critical Medimmune Inc
Priority to EP04811773A priority Critical patent/EP1689346A4/en
Priority to AU2004293034A priority patent/AU2004293034B2/en
Priority to CA002546763A priority patent/CA2546763A1/en
Priority to CN2004800407205A priority patent/CN1905899B/en
Priority to JP2006541599A priority patent/JP4860477B2/en
Publication of WO2005051307A2 publication Critical patent/WO2005051307A2/en
Publication of WO2005051307A3 publication Critical patent/WO2005051307A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-­cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
PCT/US2004/039112 2002-05-10 2004-11-19 Epha2 agonistic monoclonal antibodies and methods of use thereof WO2005051307A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04811773A EP1689346A4 (en) 2003-11-20 2004-11-19 Epha2 agonistic monoclonal antibodies and methods of use thereof
AU2004293034A AU2004293034B2 (en) 2002-05-10 2004-11-19 EphA2 agonistic monoclonal antibodies and methods of use thereof
CA002546763A CA2546763A1 (en) 2003-11-20 2004-11-19 Epha2 agonistic monoclonal antibodies and methods of use thereof
CN2004800407205A CN1905899B (en) 2003-11-20 2004-11-19 EphA2 agonistic monoclonal antibodies and methods of use thereof
JP2006541599A JP4860477B2 (en) 2003-11-20 2004-11-19 EphA2 agonistic monoclonal antibody and method of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52417703P 2003-11-20 2003-11-20
US60/524,177 2003-11-20

Publications (2)

Publication Number Publication Date
WO2005051307A2 WO2005051307A2 (en) 2005-06-09
WO2005051307A3 true WO2005051307A3 (en) 2006-09-08

Family

ID=34632874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/039112 WO2005051307A2 (en) 2002-05-10 2004-11-19 Epha2 agonistic monoclonal antibodies and methods of use thereof

Country Status (7)

Country Link
EP (1) EP1689346A4 (en)
JP (1) JP4860477B2 (en)
KR (1) KR20060135671A (en)
CN (1) CN1905899B (en)
AU (1) AU2004293034B2 (en)
CA (1) CA2546763A1 (en)
WO (1) WO2005051307A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US7662770B2 (en) 2002-05-23 2010-02-16 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220525B2 (en) 2003-03-12 2011-03-31 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
EP2287194B1 (en) 2004-03-12 2016-10-26 Vasgene Therapeutics, Inc. Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
KR20070034465A (en) 2004-03-12 2007-03-28 바스진 테라퓨틱스, 인크. Polypeptide Compounds for Inhibiting Angiogenesis and Tumor Growth
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
EP1799713B1 (en) 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
AU2006331775A1 (en) * 2005-12-21 2007-07-05 Medimmune, Llc Affinity optimized EphA2 agonistic antibodies and methods of use thereof
US20100254996A1 (en) * 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
MY150621A (en) * 2007-08-30 2014-02-14 Daiichi Sankyo Co Ltd Anti-epha2 antibody
JP5808349B2 (en) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー Biomarkers for theranosis
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
EP2595657A4 (en) * 2010-07-22 2015-09-23 Univ California Anti-tumor antigen antibodies and methods of use
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2016171242A1 (en) * 2015-04-24 2016-10-27 第一三共株式会社 Detection of epha2
CN115025217B (en) * 2022-05-13 2023-05-05 广东齐美医药生物科技集团有限公司 Use of stem cell lysate in combination with active polysaccharide and tyrosinase inhibitor in preparation of drugs or cosmetics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014292A2 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
EP1519956B1 (en) * 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
WO2005056766A2 (en) * 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012172A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CARLES-KINCH K. ET AL: "Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior", CANCER RESEARCH, vol. 62, 15 May 2002 (2002-05-15), pages 2840 - 2847, XP002904266 *
CARTER P. ET AL: "Humanization of an anti-p185HER2 antibody for human cancer therapy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 89, May 1992 (1992-05-01), pages 4285 - 4289, XP000275844 *
COFFMAN K.T. ET AL: "Differential EphA2 Epitope Display on Normal versus Malignant Cells", CANCER RESEARCH, vol. 63, 15 November 2003 (2003-11-15), pages 7907 - 7912, XP002993150 *
GUSSOW D. ET AL: "Humanization of Monoclonal Antibodies", METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 99 - 121, XP008077315 *
MORRISON ET AL.: "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 81, November 1984 (1984-11-01), pages 6851 - 6855, XP002943761 *
ORLANDI R. ET AL: "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 86, May 1989 (1989-05-01), pages 3833 - 3837, XP000026475 *
See also references of EP1689346A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4

Also Published As

Publication number Publication date
JP4860477B2 (en) 2012-01-25
AU2004293034B2 (en) 2012-02-02
EP1689346A4 (en) 2007-11-21
CA2546763A1 (en) 2005-06-09
JP2008500021A (en) 2008-01-10
EP1689346A2 (en) 2006-08-16
KR20060135671A (en) 2006-12-29
AU2004293034A1 (en) 2005-06-09
WO2005051307A2 (en) 2005-06-09
CN1905899B (en) 2011-09-28
CN1905899A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
WO2004014292A3 (en) EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
WO2005051307A3 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2006070286A3 (en) Monoclonal antibodies against nkg2a
WO2004073653A8 (en) Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
IL245462A0 (en) Humanized anti-cmet antagonists
WO2007103510A3 (en) Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
WO2005115452A3 (en) Fcϝriib-specific antibodies and methods of use thereof
PL1830881T3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
WO2003094859A3 (en) Epha2 monoclonal antibodies and methods of use thereof
WO2002094192A3 (en) Antibodies against tumor necrosis factor delta (april)
IL181473A (en) Humanized anti-beta 7 antibodies, compositions comprising them and uses thereof
EP1622589A4 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
TW200637831A (en) Triazole compounds that modulate Hsp90 activity
WO2005070126A3 (en) Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2004078144A3 (en) Diphenylethylene compounds and uses thereof
WO2007094819A3 (en) Triazole compounds that modulate hsp90 activity
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2005115453A3 (en) Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
IL201889A (en) Therapeutic compositions for the treatment of immune related disorders comprising antibodies that specifically recognize the nk 1.1 antigen or the cd56 antigen expressed by nk t cells
WO2005084377A3 (en) Combination therapy with glatiramer acetate and riluzole

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006541599

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2546763

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004293034

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067012152

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004811773

Country of ref document: EP

Ref document number: 2223/CHENP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004293034

Country of ref document: AU

Date of ref document: 20041119

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004293034

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200480040720.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004811773

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067012152

Country of ref document: KR